Filtered By:
Specialty: Cancer & Oncology
Therapy: Gene Therapy

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 68 results found since Jan 2013.

Downregulation of PLK1 by RNAi attenuates the tumorigenicity of esophageal squamous cell carcinoma cells via promoting apoptosis and inhibiting angiogenesis.
Abstract Polo-like kinase 1(PLK1) is essential for the maintenance of genomic stability during mitosis. PLK1 has been reported to be upregulated in several solid tumors, including esophageal squamous cell carcinoma (ESCC). However, the role of PLK1 in tumorigenesis of ESCC remains undetermined. We used siRNA and lentivirus-mediated PLK1 RNA interference to investigate the tumor suppressor function of PLK1 reduction in ESCC cells. Flow cytometry and Terminal deoxynuleotidyl transferase-mediated nick-end labeling assay in vitro, as well as immunohistochemitry analysis of Caspase-3 and CD31 in s.c. tumor tissue secti...
Source: Neoplasma - August 17, 2015 Category: Cancer & Oncology Authors: Zhao CL, Ju JY, Gao W, Yu WJ, Gao ZQ, Li WT Tags: Neoplasma Source Type: research

Abstract 2115: Effect of small interfering RNA targeting HPV E6/E7 gene on the regulation of TP53/Rb dynamic behaviour in cervical cancer cells
Human papillomavirus (HPV) E6 and E7 viral oncogenes are very well known to cause cervical cancer, because E6 degrades TP53 tumor suppressor protein, and E7 inactivates the tumor suppressor retinoblastoma (pRb) protein. Thus E6 and E7 oncogenes of HPV are supposed to be promising targets of gene therapy against HPV mediated cervical cancer. Here, we attempted to study the regulation of TP53/pRb proteins dynamic behaviour after HPV E6/E7 small interfering RNA (siRNA) transfection in cervical cancer cells. HPV positive (HeLa and Caski) cell lines were selected for these experiments. Herein, we also validated the dynamics of ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Rajasekaran, N., Jung, H. S., Kim, Y. D., Kim, D. A., Ha, T. K., Na, Y. H., Shin, Y. k. Tags: Molecular and Cellular Biology Source Type: research

Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway
Abstract Paclitaxel is recommended as a first-line chemotherapeutic agent against ovarian cancer, but drug resistance becomes a major limitation of its success clinically. The key molecule or mechanism associated with paclitaxel resistance in ovarian cancer still remains unclear. Sex-determining region Y-box 2 (SOX2) is of vital importance in the regulation of stem cell proliferation and carcinogenesis. The aim of this study was to evaluate the role of SOX2 in ovarian cancer tumorigenesis and paclitaxel resistance. In the present study, the expression of SOX2 was examined by immunohistochemistry (IHC) and real-tim...
Source: Tumor Biology - July 11, 2015 Category: Cancer & Oncology Source Type: research

Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth
In this study, we evaluated the expression level of UHRF1 in ovarian cancer. UHRF1 levels in paired ovarian cancer tissues and adjacent normal tissues from 80 ovarian cancer patients were detected using relative quantitatively PCR and Western blot. Small interfering RNA (siRNA) was introduced in two human ovarian cancer cell lines (SKOV-3 and OVCAR-3) to downregulate the expression of UHRF1. The proliferation of siRNA-treated cells was examined using cell counting kit-8 (CCK-8) assay. The growth of these cells showed a remarkable decrease. Moreover, flow cytometric and Hoechst 33342 assays were used to detect the apoptosis...
Source: Tumor Biology - June 13, 2015 Category: Cancer & Oncology Source Type: research

CSN5 silencing inhibits invasion and arrests cell cycle progression in human colorectal cancer SW480 and LS174T cells in vitro.
Abstract CSN5 has been implicated as a candidate oncogene in human cancers by genetic linkage with activation of the poor-prognosis, wound response gene expression signature. The present study aimed to investigate the effect of silencing CSN5 on invasion and cell cycle progression of human colorectal cancer cells, and to determine the potential molecular mechanisms that are involved. The CSN5 specific small interfering RNA (shRNA) plasmid vector was constructed and then transfected into colorectal cancer cells. The expression of CSN5 mRNA and protein was detected by quantitative polymerase chain reaction and weste...
Source: Clinical Colorectal Cancer - June 7, 2015 Category: Cancer & Oncology Authors: Zhong G, Li H, Shan T, Zhang N Tags: Int J Clin Exp Pathol Source Type: research

Down-regulated long non-coding RNA H19 inhibits carcinogenesis of renal cell carcinoma.
Abstract Long non-coding RNAs (lncRNAs) have been shown to have important regulatory roles in cancer biology. LncRNA H19 has been recently shown to be upregulated and play important roles in several cancers such as breast cancer, bladder cancer, and gastric cancer. However, the role of H19 in clear cell renal carcinoma (ccRCC) remains largely unknown.The expression levels of lncRNA H19 in ccRCC tissues and renal cancer cell lines were evaluated by quantitative Real-time PCR (qRT-PCR). And its association with overall survival of patients was analyzed by statistical analysis. Small interfering RNA (siRNA) was used ...
Source: Neoplasma - April 13, 2015 Category: Cancer & Oncology Authors: Wang L, Jia X, Zhao X, Cai Y, Zhang J, Liu J, Zhen H, Wang T, Tang X, Liu Y, Wang J Tags: Neoplasma Source Type: research

P5.07 * Targeting AKT2 signalling events: improving therapeutic outcomes through cancer stemness modulation
Conclusion: This study reveals the importance of AKT2 knockdown for E-cadherin restoration and metastatic potential decrease in mesenchymal BC cells. These results highlight AKT2 as a promising target for future gene therapy strategies concerning the prevention against CSC malignance and cancer recurrence.
Source: Annals of Oncology - March 20, 2015 Category: Cancer & Oncology Authors: Rafael, D., Gener, P., Pereira, L., Florindo, H., Schwartz, S., Videira, M. Tags: Poster session 5: New drugs/targets: signaling pathways Source Type: research

Epidermal growth factor activates telomerase activity by direct binding of Ets-2 to hTERT promoter in lung cancer cells
In this study, we investigated molecular mechanisms of the effect of EGF (epidermal growth factor) on regulating hTERT (human telomerase reverse transcriptase) expression. To elucidate specific transcription factors involved in EGF-stimulated hTERT transcription in A549 and H1299 lung cancer cells, transcription factors drives hTERT promoter activity, such as Myc, Mad, and Ets-2, was evaluated on luciferase reporter assay. The upregulation of hTERT promoter by Ets-2 and Myc were abolished by Mad. Using DAPA (DNA affinity precipitation assay), Ets-2 binding to SNP (T) was stronger than Ets-2 binding to SNP (C) at −245 bp...
Source: Tumor Biology - February 13, 2015 Category: Cancer & Oncology Source Type: research

Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin.
Authors: Qu Y, Xia P, Zhang S, Pan S, Zhao J Abstract X-chromosome-linked inhibitor of apoptosis protein (XIAP) is an important member of the inhibitors of apoptosis (IAP) family. It has been shown that XIAP promotes the invasion, metastasis, growth and survival of malignant cells, and confers resistance to some chemotherapeutic drugs in various types of cancer. However, little is known regarding its detailed role in osteosarcoma (OS). In the present study, we first investigated the expression of XIAP in OS tissues, and an increased expression of XIAP in OS tissues compared to adjacent non-tumor tissue was ident...
Source: Oncology Reports - January 16, 2015 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Abstract 1453: MicroRNA replacement and RNAi-mediated silencing of ALK as combined targeted therapies for neuroblastoma
The effective treatment of advanced Neuroblastoma (NB) is still a challenge in pediatric oncology, because the clinical use of most therapeutics is limited by insufficient drug delivery to the tumor and high systemic toxicity. The discovery of the RNAi has great promise for anti-cancer therapeutics but, as in high-grade solid tumors a single ‘oncogene addiction’ is rare, multi-'gene' target combinations are required and a targeted delivery system is mandatory to successfully translate RNAi-based therapeutics into the clinics. It is now ascertained the master role of ALK and related genes such as PHOX2B, able to promote...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Perri, P., Paolo, D. D., Priddy, L., Fiore, A. D., Brignole, C., Pastorino, F., Brown, D., Ponzoni, M. Tags: Molecular and Cellular Biology Source Type: research

Application of Target Peptide in siRNA Delivery 
for the Research of Lung Cancer Therapy
This article will make a brief overview of target peptides applying in siRNA dilivery for the research of lung cancer treatment. DOI: 10.3779/j.issn.1009-3419.2014.09.06
Source: Chinese Journal of Lung Cancer - September 19, 2014 Category: Cancer & Oncology Source Type: research

Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells
maagacli
Source: Cancer Gene Therapy - June 6, 2014 Category: Cancer & Oncology Authors: M KoldehoffD W BeelenA H Elmaagacli Source Type: research

Superparamagnetic iron oxide nanoparticles mediated 131I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice
Conclusions: EMF-guided 131I-hVEGF siRNA/SilenceMag exhibited an antitumor effect. The synergic therapy of 131I-hVEGF siRNA/SilenceMag might be a promising future treatment option against HCC with the dual functional properties of tumor therapy and imaging.
Source: BMC Cancer - February 21, 2014 Category: Cancer & Oncology Authors: Jing ChenShu ZhuLiangqian TongJiansha LiFei ChenYunfeng HanMing ZhaoWei Xiong Source Type: research

FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer
Conclusions: These results suggest that FOXA1 promotes cell proliferation by AR and activates Notch pathway. It indicated that FOXA1 and AR may serve as potential gene therapy in EC.
Source: BMC Cancer - February 11, 2014 Category: Cancer & Oncology Authors: Meiting QiuWei BaoJingyun WangTingting YangXiaoying HeYun LiaoXiaoping Wan Source Type: research

Silencing of Glucose Transporter Protein-1 by RNA Interference Inhibits Human Osteosarcoma Mg63 Cells Growth in vivo.
Abstract While knock-down of glucose transporter protein 1 (GLUT-1) inhibited various human cancer cell growth in vitro and in vivo, including osteosarcoma cell growth in vitro, there has been no report on whether knock-down of GLUT-1 by siRNA may inhibit osteosarcoma cell growth in vivo. We hypothesized that siRNA may inhibit osteosarcoma cell growth in vivo. We introduced siRNA-GLUT-1 by lentivirus into MG63 osteosarcoma cells which were xenograted into nude mice. Immunohistochemical staining, Western blot and reverse transcriptase quantitative (RT-qPCR) were used to determine GLUT-1 protein and mRNA expression ...
Source: Technology in Cancer Research and Treatment - February 3, 2014 Category: Cancer & Oncology Authors: Jian F, Yuan F, Jiong M, Zhu XZ, Yu GR, Lu DD Tags: Technol Cancer Res Treat Source Type: research